Durvalumab and tremelimumab combination therapy versus durvalumab or tremelimumab monotherapy for patients with solid tumors: A systematic review and meta-analysis

BACKGROUND: The combination of durvalumab and tremelimumab results in clinical benefit, with a tolerable safety profile in patients with solid tumors. OBJECTIVE: To evaluate the efficacy and safety of durvalumab in combination with tremelimumab compared with either drug alone. METHODS: The online da...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Bi-Cheng, Li, Peng-Cheng, Fan, Ji-Quan, Lin, Guo-He, Liu, Quentin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360234/
https://www.ncbi.nlm.nih.gov/pubmed/32664183
http://dx.doi.org/10.1097/MD.0000000000021273

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360234/
https://www.ncbi.nlm.nih.gov/pubmed/32664183
http://dx.doi.org/10.1097/MD.0000000000021273

Ejemplares similares